Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD1916 vs Semaglutide in Obesity
NCT06604624Phase 3Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HD1916 in obesity, sponsored by CSPC Baike Biopharmaceutical. Started Sep 2024; status: completed.
02
Drugs
HD1916
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06604624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06604624.